Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program

BACKGROUND: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Patients with inflammatory bowel disease are susceptible to Clostridium difficile infection (CDI). Here, we evaluate CDI in the tofacitinib UC clinical program. METHODS: Events fro...

Descripción completa

Detalles Bibliográficos
Autores principales: Loftus, Edward V, Baumgart, Daniel C, Gecse, Krisztina, Kinnucan, Jami A, Connelly, Susan B, Salese, Leonardo, Su, Chinyu, Kwok, Kenneth K, Woolcott, John C, Armuzzi, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152280/
https://www.ncbi.nlm.nih.gov/pubmed/35792493
http://dx.doi.org/10.1093/ibd/izac139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152280/
https://www.ncbi.nlm.nih.gov/pubmed/35792493
http://dx.doi.org/10.1093/ibd/izac139

Ejemplares similares